Janssen Biotech Unable To Rewrite History and Save Remicade Patent
Client Alert | less than 1 min read | 01.25.18
Contacts
Insights
Client Alert | 7 min read | 04.20.26
EU Pharma Package: The “Bolar” Exemption Compromise Proposal
In our sixth alert in this EU Pharma Package Series, we provided an analysis of the history and interpretation issues for another highly debated topic: the “Bolar” exemption.
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
Client Alert | 1 min read | 04.17.26
Client Alert | 3 min read | 04.17.26
